Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data

<i>Background and </i><i>O</i><i>bjective</i>: Radium-223 dichloride (Xofigo&#174;) is a calcium mimetic agent approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease...

Full description

Bibliographic Details
Main Authors: Theodoros G. Soldatos, Ioannis Iakovou, Christos Sachpekidis
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Medicina
Subjects:
prostate cancer
bone metastases
radium-223 dichloride (Xofigo®)
side effects
real world data
data mining
pharmacoepidemiology
proportional reporting ratio
Online Access:https://www.mdpi.com/1010-660X/55/5/149

Internet

https://www.mdpi.com/1010-660X/55/5/149

Similar Items